Literature DB >> 9600092

Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.

K Matsuzaki1, N Udagawa, N Takahashi, K Yamaguchi, H Yasuda, N Shima, T Morinaga, Y Toyama, Y Yabe, K Higashio, T Suda.   

Abstract

We have reported that osteoclast differentiation factor (ODF) expressed on the plasma membrane of osteoblasts/ stromal cells is a ligand for osteoclastogenesis inhibitory factor (OCIF). A genetically engineered soluble form of ODF (sODF) induced osteoclast-like multinucleated cells (OCLs) in the presence of M-CSF in mouse spleen cell cultures. Osteoblasts/stromal cells were not required in this process. To elucidate the mechanism of human osteoclastogenesis, human peripheral blood mononuclear cells (PBMCs) were cultured for 7 days with sODF and human M-CSF in the presence or absence of dexamethasone. Treatment of human PBMCs with sODF together with M-CSF induced OCLs, which expressed tartrate-resistant acid phosphatase and vitronectin receptors, produced cAMP in response to calcitonin, and formed resorption pits on dentine slices. OCLs were also formed from the adherent cell population of human PBMCs. Dexamethasone was required for human OCL formation in culture of whole PBMCs but not in culture of the adherent cell population. OCL formation was strongly inhibited by OCIF simultaneously added. These results clearly indicate that like in mouse osteoclastogenesis, ODF is a critical factor for human osteoclastogenesis. The present study also indicates that OCIF acts as a naturally occurring decoy receptor for ODF in inhibiting signal transduction in human osteoclast formation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9600092     DOI: 10.1006/bbrc.1998.8586

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  57 in total

1.  IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis.

Authors:  S Kotake; N Udagawa; N Takahashi; K Matsuzaki; K Itoh; S Ishiyama; S Saito; K Inoue; N Kamatani; M T Gillespie; T J Martin; T Suda
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

2.  Spontaneous and induced osteoclastogenic behaviour of human peripheral blood mononuclear cells and their CD14(+) and CD14(-) cell fractions.

Authors:  J Costa-Rodrigues; A Fernandes; M H Fernandes
Journal:  Cell Prolif       Date:  2011-10       Impact factor: 6.831

3.  The association between RANKL and Osteoprotegerin gene polymorphisms with breast cancer.

Authors:  Heba S Omar; Olfat G Shaker; Yasser H Nassar; Samar A Marzouk; Mohamed S ElMarzouky
Journal:  Mol Cell Biochem       Date:  2015-02-28       Impact factor: 3.396

Review 4.  Osteoclasts: New Insights.

Authors:  Xu Feng; Steven L Teitelbaum
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

Review 5.  Historically significant events in the discovery of RANK/RANKL/OPG.

Authors:  T John Martin
Journal:  World J Orthop       Date:  2013-10-18

Review 6.  The roles of lipid oxidation products and receptor activator of nuclear factor-κB signaling in atherosclerotic calcification.

Authors:  Linda Demer; Yin Tintut
Journal:  Circ Res       Date:  2011-06-10       Impact factor: 17.367

7.  sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.

Authors:  K K Doumouchtsis; A I Kostakis; S K Doumouchtsis; M P Tziamalis; C Tsigris; M A Kostaki; D N Perrea
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

8.  Immunohistological identification of receptor activator of NF-kappaB ligand (RANKL) in human, ovine and bovine bone tissues.

Authors:  R J Mueller; R G Richards
Journal:  J Mater Sci Mater Med       Date:  2004-04       Impact factor: 3.896

Review 9.  Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit.

Authors:  Natalie A Sims; T John Martin
Journal:  Bonekey Rep       Date:  2014-01-08

Review 10.  Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

Authors:  J L Sottnik; E T Keller
Journal:  Curr Mol Med       Date:  2013-05       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.